On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON ...
Fintel on MSN6d
Leerink Partners Upgrades Beam Therapeutics (BEAM)Fintel reports that on November 6, 2024, Leerink Partners upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from ...
Leerink Partners has recently raised Beam Therapeutics Inc (BEAM) stock to Outperform rating, as announced on November 6, 2024, according to Finviz. Earlier, on October 16, 2024, Scotiabank had ...
Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...
H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on BEAM stock, giving a Buy rating today. Patrick Trucchio has ...
Beam Therapeutics (BEAM) stock gains as Leerink upgrades the biotech despite a fatality in a gene editing study, citing an ...
Beam Therapeutics (NASDAQ:BEAM) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that ...
Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM.
Beam Therapeutics (BEAM) stock falls as patient dies after receiving the company's gene editing therapy.in an early-stage ...
BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development. Stock rises in pre-market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback